Role of the \textit{ABCG8} 19H risk allele in cholesterol absorption and gallstone disease

Olga Renner\textsuperscript{1}\textsuperscript{*}, Dieter Lütjohann\textsuperscript{2}, Dominique Richter\textsuperscript{1}, André Strohmeyer\textsuperscript{1}, Silke Schimmel\textsuperscript{1}, Oliver Müller\textsuperscript{3}, Eduard F Stange\textsuperscript{3}\textsuperscript{*} and Simone Harsch\textsuperscript{1}

Abstract

\textbf{Background:} Gallstone disease is associated with p.D19H of \textit{ABCG8} as well as alterations of cholesterol and bile acid metabolism. However, molecular mechanisms have not been fully elucidated. It is important to understand the link between the sterol transporters \textit{ABCG5/8} and \textit{NPC1L1} and intestinal cholesterol absorption as well as \textit{de novo} synthesis in gallstone patients stratified according to 19H risk allele. Moreover, the functional importance of the 19H variant on intestinal \textit{ABCG8} feature remains to be clarified.

\textbf{Methods:} Measurements of serum surrogate markers of cholesterol absorption (plant sterols: sitosterol, campesterol) and synthesis (cholesterol precursor: lathosterol) were carried out by gas chromatography/mass spectrometry (GC/MS). For expression studies, total RNA was isolated from 168 ileal biopsies of study participants with (34) and without gallstone disease (134). Messenger RNA was measured by LightCycler real-time PCR. Genomic DNA was obtained from blood leukocytes. Genotype frequencies of p.D19H were established using MALDI-TOF mass spectrometry.

\textbf{Results:} Compared to controls, cholesterol absorption but not synthesis in gallstone carriers was diminished by about 21% based on low serum sitosterol ($P = 0.0269$) and campesterol ($P = 0.0231$) to cholesterol ratios. D19H was found to be significantly associated with gallstones (odds ratio [OR] = 2.9, $P = 0.0220$, 95% confidence interval [CI]:1.22-6.89), particularly in the overweight cohort (OR = 3.2, $P = 0.0430$, 95% CI:1.07-9.26). Cholesterol absorption was about 24% lower in individuals carrying p.D19H compared to wild type ($P$ \textit{sitosterol} = 0.0080, $P$ \textit{campesterol} = 0.0206). Moreover, irrespective of phenotype, carriers of p.D19H displayed a significant lower absorption than carriers of the major allele. The most pronounced effect on cholesterol absorption ratio was observed for serum campesterol levels (wild type controls to mutated controls 28%, $P = 0.0347$ and wild type controls to gallstone carriers with 19H allele 37%, $P = 0.0030$). Notably, \textit{ABCG5/8} and \textit{NPC1L1} expression was similar in gallstone carriers and controls regardless of p.D19H presence.

\textbf{Conclusions:} Both gallstone disease and p.D19H of \textit{ABCG8} are associated with diminished cholesterol absorption. However, p.D19H is not responsible for the differences in small intestinal sterol transporter expression.

Background

Gallstone disease is a frequent health problem affecting 10-20% of the Western population [1]. An imbalance between cholesterol, bile acids, and phospholipids is a key factor for cholesterol gallstone formation [2] but the metabolic cause of this disturbance is still unclear. Gallstone carriers and controls exhibit basic differences in cholesterol and bile acid homeostasis [3,4]. In the presence of normal dietary cholesterol its absorption tended to be diminished in gallstone carriers whereas synthesis was induced [3]. However, the contribution of newly synthesized to biliary cholesterol in animals and man is small [5-8] and the origin of excess biliary cholesterol remains uncertain. Moreover, gallstone carriers respond to an increased cholesterol load with an elevated biliary cholesterol secretion and exhibit a diminished hepatic \textit{de novo} cholesterol synthesis [3]. Furthermore, the regulation of cholesterol synthesis in overweight persons, prone to develop gallstones, differs from the lean individuals and is feedback inhibited after the application of long-term high...
cholesterol diet [9]. Gallstone carriers also exhibit a reduction in the primary bile acid pool size, an increase of the biliary fraction of secondary bile acids, reduced gallbladder motility as well as a prolonged intestinal transit time [10,11]. The mechanism behind the low primary bile acids in bile may be a diminished expression of bile acid transporters in the terminal ileum [12,13]. The ultimate consequence is cholesterol supersaturation in the gallbladder bile, leading to crystal precipitation of free cholesterol and gallstone formation [2,3,10,14].

Responsible for cholesterol transport in the human gut are the heterodimeric ATP-binding cassette transporter (ABCG5/8) and Niemann-PickC1-Like 1 Protein (NPC1L1). Following incorporation into micelles, dietary as well as biliary cholesterol is available for uptake from the intestinal lumen through the importers NPC1L1 [15]. This protein is localized at the apical membrane of the enterocytes [16] and contributes to intestinal cholesterol homeostasis [15-18]. The heterodimeric sterol transporter ABCG5/8 determines hepatobiliary cholesterol secretion and cholesterol efflux out of the enterocytes back into the intestinal bile, leading to crystal precipitation of free cholesterol and gallstone formation [2,3,10,14].

Human and murine studies support a strong genetic background of gallstone risk [26-28]. Most prominently associated with gallstone disease is the D19H polymorphism of the ABCG8 gene [29]. In healthy individuals, the D19H polymorphism was associated with low cholesterol absorption [30]. Similarly, Gylling described low serum total cholesterol and cholesterol absorption in the cohort of mildly to moderately hypercholesterolemic subjects with the 19H allele [31]. Recently, the study of Krawczyk showed that cholesterol absorption was significantly lower and de novo synthesis higher in gallstone carriers [4] but this was independent of the D19H polymorphism.

The present study therefore addressed the following questions: i) are both, low cholesterol absorption and increased de novo cholesterol synthesis indeed common in gallstone carriers, ii) is the expression of intestinal cholesterol transporters and their transcription factors different in gallstone carriers, iii) does the D19H polymorphism of the ABCG8 gene affect any of these parameters?

Methods

Ethics statement

The local ethics committee (ethics committee of the University Hospital of Tuebingen and University Tuebingen) approved this study and all subjects gave written informed consent prior to participation.

Subjects

Study subjects were recruited from the contingent of individuals invited to undergo routine colonoscopy according to the recommendations of German Health Organisation and for cancer prevention. Individuals, who agreed the participation in the study, were personally interviewed and seen by the physicians regarding their health conditions. Subjects included in this study had a) normal serum lipid values and no history of taking lipid-lowering drugs or drugs interfering with bile acid uptake, b) no known medical conditions affecting lipid metabolism, c) normal liver function and no signs of haemolysis or other conditions associated with pigment stones, d) no intestinal surgery and e) no impaired nutritional status. None of the gallstone carriers or controls had symptomatic gallstone disease, abnormal liver function, elevated serum lipids or inflammation in the ileum. Biopsies and blood samples were collected from a total of 168 individuals in the Robert Bosch Hospital in Stuttgart. Blood samples (3–5 mL) were used for cholesterol and phytosterol measurements as well as for genotyping investigations. Up to eight ileal biopsy specimens were taken from each participant (for this investigation two separate samples, each about 8–10 mg, were used). 134 subjects were healthy controls and 34 individuals had gallstones. The presence or absence of gallstones was confirmed by ultrasound. Serum triglycerides and cholesterol levels were analysed by standard clinical tests.

Measurements of sterol synthesis and absorption

Measurements of the non-cholesterol sterols lathosterol, campesterol and sitosterol from serum samples were carried out by GC-MS as reported previously [32]. Cholesterol absorption was given as ratio of sitosterol or campesterol to total cholesterol and cholesterol synthesis was calculated as the ratio of lathosterol to cholesterol [33].

Real-time quantitative reverse transcription – polymerase chain reaction (RT-PCR)

Total RNA was isolated from whole biopsy specimen using TRizol extraction procedure (Invitrogen) according to the manufacturer’s protocol. The integrity, quality and quantity of RNA were analysed by gel electrophoresis and absorption measurement. Four hundred ng of total RNA was reverse transcribed using the (AMV)-reverse transcriptase system (Promega) and random hexamers. RT-PCR was performed with LightCycler sequence detection system (Roche Diagnostics) as reported previously [12,13]. Primer sequences used for amplification of human ABCG5, ABCG8, NPC1L1, LXRα, LXRβ, HNF1α, HNF4α, PPARβ and SREBP2 are listed in Table 1. Target specific PCR conditions were: 95°C for 5 min, 40 cycles at 95°C for 10 s, followed by 60°C for 5 s, then 72°C for 7 s. For the quantification of NPC1L1 a PCR of 50 cycles was necessary. At the end of the PCR, a dissociation curve was performed.
The quantity for any given transcript was calculated using the second derivative maximum method according to manufacturer’s instructions. Gene-specific plasmids served as control templates with specific oligonucleotide primer pairs. All measurements were carried out in duplicate.

**Plasmid construct**
Plasmids were constructed with the TOPO TA Cloning Kit (Invitrogen) according to manufacturer’s recommendations. Four μL PCR product were subcloned into the EcoRI sites of a 2.1 TOPO TA cloning vector. Transformation was performed with two μl of the ligation onset to TOP 10 cells (E. coli) and spread to agar plates appended with X-Gal and ampicillin. The sample was incubated overnight at 37°C. White colonies were picked and purified/isolated with the Miniprep kit (Qiagen). The positive clones were verified by DNA sequencing.

**Western blot analysis**
For protein analysis a separate whole ileal mucosal biopsy was required. Total protein was isolated using TRIzol Reagent (Invitrogen). Protein concentration was determined applying the Bradford assay (Bio-Rad). Samples were heated at 95°C for 5 min. A total of six μg for ABCG8 and 15 μg for ABCG5/NPC1L1 protein were loaded and then electrophoresed (90 min, 100 V) on self-cast SDS-PAGE gels (ABCG5/8 10%, NPC1L1 8%) and blotted on nitrocellulose (0.45 μm, Whatman). After blotting, membranes were blocked for 1 h with 5% non-fat dry-milk (NFDM) in Tris-buffered saline containing 0.1% Tween 20 (TBST). Hereafter, membranes were incubated overnight with primary antibodies (ABCG5: ab45279/Abcam diluted 1:1,000 in 3% NFDM/TBST and 1% of Roti®-Block reagent (Roth); ABCG8: NB400-110/Novus Biologicals diluted 1:3,000 in 5% NFDM/TBST and NPC1L1: EPR5717/ab124801/Abcam diluted 1:200 in 3% NFDM/TBST). After being washed five times for 5 min blots were probed with the secondary antibody, peroxidase-conjugated goat anti-rabbit IgG (1:10,000, Dianova) and exposed to a chemiluminescent reagent (SuperSignal® West Dura; Pierce). The immunoreactive band was obtained at the predicted size of 75 kDa representing ABCG5 or ABCG8 and 145 kDa representing the NPC1L1 monomer. Bands were photographed and immunoquantitation was accomplished by densitometric analysis using the software AIDA (Raytest). To account for variability in the amounts of enterocytes in biopsy specimens, villin contents of all samples were determined. Therefore membranes were incubated with a primary antibody against human villin (1:2,000, Chemicon International), followed by incubation with the secondary peroxidase-conjugated anti-mouse IgG antibody (1:1,500, Oncogene). Protein staining was obtained at the predicted size of 95 kDa. All measurements were carried out in duplicate.

**Isolation of DNA**
Genomic DNA was extracted from peripheral blood leukocytes by standard methods using the Qiagen system.

### Table 1 Primer sequences used for QRT-PCR

| Fragment  | Primer | Sequence | Product size |
|-----------|--------|----------|--------------|
| Exon 9/10 | ABCG5 F | 5’ – CGGTAGGTCTCTCTTTTACCA – 3’ | 152 |
|           | ABCG5 R | 5’ – AGTGCATTAGCCGAGCATCAT – 3’ | 152 |
| Exon 10/11| ABCG8 F | 5’ – GTGGCTGTGCTCTCTGGTT – 3’ | 84 |
|           | ABCG8 R | 5’ – CTAGAAGAAGGGGCATGTC – 3’ | 84 |
| Exon 17/18| NPC1L1 F | 5’ – GTGGGGCATACGTTACAAGT – 3’ | 166 |
|           | NPC1L1 R | 5’ – AAGACCCGCACCTCCCATAG – 3’ | 166 |
| Exon 4/5  | LXRA F  | 5’ – TCAAGCAGATCTGTCTCTTCT – 3’ | 213 |
|           | LXRA R  | 5’ – TCAAGCCGGATCTCTCTTCT – 3’ | 213 |
| Exon 7/8  | LXRβ F  | 5’ – TAAGCAACTGCCTGTTCTC – 3’ | 200 |
|           | LXRβ R  | 5’ – ACTCGAAGATGGGTTGATG – 3’ | 200 |
| Exon 8/10 | HNF1α F | 5’ – CACGCCCAACAAAGAGTCT – 3’ | 165 |
|           | HNF1α R | 5’ – CACGCGTGCTGAGACACTG – 3’ | 165 |
| Exon 9/10 | HNF4α F | 5’ – ATGCCCTGGGCTGTC – 3’ | 235 |
|           | HNF4α R | 5’ – TCCGGTGCTGATCCG – 3’ | 235 |
| Exon 4/5  | SREB2 F | 5’ – CACGCTCGATCATCAAGACA – 3’ | 202 |
|           | SREB2 R | 5’ – CTTTCTTCGCCCATATCA – 3’ | 202 |
| Exon 4/5  | PPARα5 F | 5’ – ATGGAGGAGCCACAGAGAGGC – 3’ | 200 |
|           | PPARα5 R | 5’ – GCATGAGGCAGGCACAGGC – 3’ | 200 |
(QIAamp DNA blood kit/QIAGEN DNA Blood Midi Prep) according to manufacturer’s recommendations.

Genotyping
The D19H SNP analysis of ABCG8 was performed with blood DNA using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) of allele specific primer extension products as reported previously [34], applying the following primer sequences:

1st-primer: ACGTTGGATGAGGAGGAGGGCTGC
2nd-primer: ACGTTGGATGACTTCCCATTGACTCA
extension primer: TGCTCACTCAGGAGGATG.

For quality control no-template controls in all plates and repeated analysis of 10% of randomly selected samples were performed.

Statistics
For statistical analysis GraphPad Prism version 5 was used (GraphPad Software, San Diego, Ca, USA). Clinical characteristics of study participants and all data are presented as means ± standard error of the mean (SEM). Differences between groups (anthropometric and metabolic characteristics (age, body mass index (BMI), total cholesterol, and total triglycerides), cholesterol absorption and synthesis ratios and all expression data) were investigated using the two-tailed Mann–Whitney U-test. All correlations (of expression values as well as of cholesterol absorption and synthesis ratios) between variables were analysed with Spearman’s correlation rank test. Observed and expected genotype frequencies within the study population were compared by means of Hardy–Weinberg equilibrium calculations [35]. Data were considered in Hardy–Weinberg equilibrium when P-values were >0.05. Statistical analysis of genotype frequency differences between gallstone carriers and controls was done using two-sided Fisher’s exact test as appropriate. Odds ratios (ORs) together with a 95% confidence interval (CI) are given as risk measures for the development of gallstones. All statistical tests were two-tailed and a P-value of <0.05 was considered as statistically significant.

Results
Characteristics of the study cohort
Several relevant anthropometric and metabolic characteristics (age, serum cholesterol and triglyceride levels) of the participants did not differ significantly and are summarized in Table 2. Therefore, the total study cohort was stratified in two weight groups. The calculation of anthropometric data reveal a mean age of 57 years in the control group and 61 years in the gallstone carrier group. As weight also depends on age [36-40], in the present study the normal weight group was defined as BMI ≤ 25.4, individuals with BMI > 25.4 were regarded as overweight. Since the percentage of overweight subjects was higher among gallstone carriers (68%) than among control individuals (44%), the mean body mass index was slightly higher in the gallstone group (BMI = 26.6) compared to controls (BMI = 25.2) (P = 0.0378).

Cholesterol absorption and synthesis in gallstone disease
Cholesterol absorption based on the serum sitosterol/cholesterol ratio correlated well with the campesterol/cholesterol ratio (r = 0.90, P < 0.0001, Spearman’s rank test). Interestingly, in the total cohort including both weight groups, cholesterol absorption was significantly lower by about 21% in gallstone carriers compared to controls.

Table 2 Anthropometric and metabolic characteristics of the Stuttgart study cohort

| Parameter                      | Total                  | Controls | Gallstone carriers | Controls | Gallstone carriers | Normal weight | Overweight | Controls | Gallstone carriers |
|--------------------------------|------------------------|----------|--------------------|----------|--------------------|---------------|------------|----------|--------------------|
| Number                         |                        | 134      | 34                 | 75       | 11                 | 59            | 23         |          |                    |
| Age (years)                    | 57 ± 1.1               | 61 ± 1.9 | 55 ± 1.5           | 63 ± 3.6 | 59 ± 1.4           | 60 ± 2.3      |            |          |                    |
| BMI (kg/m²)                    | 25.2 ± 0.3             | 26.6 ± 0.6 | 22.7 ± 0.3         | 23.3 ± 0.6 | 28.4 ± 0.4         | 28.2 ± 0.6    |            |          |                    |
| Total cholesterol (mg/dL)      | 214 ± 3.7              | 207 ± 6.2 | 211 ± 4.7          | 214 ± 6.3 | 217 ± 6.0          | 203 ± 8.8     |            |          |                    |
| Total triglycerides (mg/dL)    | 121 ± 6.1              | 126 ± 7.8 | 101 ± 6.8          | 125 ± 14.2 | 143 ± 9.9          | 127 ± 9.5     |            |          |                    |
| Lathosterol:Cholesterol (µg/mg)| 1.15 ± 0.06            | 1.33 ± 0.15  | 0.99 ± 0.07        | 1.22 ± 0.26 | 1.33 ± 0.09*      | 1.39 ± 0.18   |            |          |                    |
| Sitosterol:Cholesterol (µg/mg) | 1.23 ± 0.06            | 0.97 ± 0.08  | 1.36 ± 0.09        | 1.11 ± 0.19 | 1.06 ± 0.07*      | 0.90 ± 0.06   |            |          |                    |
| Campesterol:Cholesterol (µg/mg)| 1.47 ± 0.07            | 1.16 ± 0.11  | 1.67 ± 0.12        | 1.23 ± 0.24 | 1.24 ± 0.08*      | 1.12 ± 0.11   |            |          |                    |

BMI = body mass index.

Values are given as means ± SEM (standard error of the mean).

Significance between the controls and gallstone carriers was analysed with Mann–Whitney U-test (nonparametric, two-tailed).

Normal weight subgroup is defined as BMI ≤ 25.4, overweight subgroup as BMI > 25.4.

P-values <0.05 were considered as statistically significant.

Controls vs. gallstone carriers: *P = 0.0378, #P = 0.0269 (21%), $P = 0.0231 (21%), @ (16%). No adjustment in the total group.

Normal weight persons vs. overweight individuals: $P = 0.0028 after adjustment (factor 6) P = 0.0168, $P = 0.0044 after adjustment P = 0.0264, $P = 0.0065 after adjustment P = 0.039.
The correlation between hepatic cholesterol synthesis and intestinal absorption was inverse and statistically significant (sitosterol/lathosterol $\rho = -0.43$, $P < 0.0001$; campesterol/lathosterol $\rho = -0.38$, $P < 0.0001$, Spearman’s rank test). In principle, these results were similar in female and male subpopulations when analysed separately, as shown in Additional file 1: Table S1C and D.

Overweight controls exhibited a higher synthesis (+33% $P = 0.0028$) and lower absorption (sitosterol $-22\%$ $P = 0.0044$; campesterol $-26\%$ $P = 0.0065$) rate than normal weight persons. Remarkably, in the subgroups the rate of cholesterol synthesis tended to be higher (4-22%, ns) and of cholesterol absorption lower (on average $\sim 17\%$, ns) in gallstone individuals than in controls. However, none of these differences between gallstone carriers and controls were statistically significant.

Ileal expression of sterol transporters and their relevant transcription factors in gallstone disease

Next, the ileal expression patterns of the three relevant sterol transporters ABCG8, ABCG5 and NPC1L1 were analysed (Figure 1). Regarding sterol exporter ABCG8 and ABCG5, no significant changes in expression were apparent when stratified according to gallstones (Figure 1A and B), also not within the different weight groups. In comparison with the exporters detailed above, ileal expression of the NPC1L1 importer was rather low (Figure 1C). Only normal weight stone-carriers exhibited a reduced expression by 80% compared to respective controls ($P = 0.0417$), whereas all other groups showed no relevant and significant expression differences. As shown in Figure 1D, comparable expression patterns could be stated on protein levels. The correlation analyses by Spearman’s rank test between transporters showed the following moderate to small correlation coefficients: $ABCG5/ABCG8 \rho = 0.50$, $P = 0.0001$; $ABCG5/$
Table 3 Mean values of mRNA transcript expression in ileal mucosa of important transcription factors in gallstone carriers and healthy controls

| Group | Target (Mean ± SEM) | Transcripts/10 ng mRNA | Overweight |
|-------|--------------------|------------------------|------------|
|       | Controls (n = 95)   | Gallstone carriers (n = 29) | Controls (n = 55) | Gallstone carriers (n = 9) | Controls (n = 40) | Gallstone carriers (n = 20) |
|       |                    |                        |             |                        |                   |                        |
| LXRα  | 70261 ± 4308       | 70004 ± 6774           | 75035 ± 6026 63318 ± 12203 | 32361 ± 3821 40781 ± 7426 | 63853 ± 5964 73544 ± 8245 |
| LXRβ  | 36208 ± 2570       | 37337 ± 5445           | 39285 ± 3445 30067 ± 6295 | 32361 ± 3821 40781 ± 7426 | 4944 ± 542 7616 ± 1183* |
| HNF1α | 5282 ± 362         | 7037 ± 864             | 5555 ± 488 5814 ± 953 | 4939 ± 5115 56615 ± 14955 | 7060 ± 817 8537 ± 1304 |
| HNF4α | 48814 ± 3407       | 53086 ± 10701          | 51632 ± 4561 45244 ± 9990 | 44939 ± 5115 56615 ± 14955 | 7060 ± 817 8537 ± 1304 |
| PPARδ | 7326 ± 574         | 7985 ± 999             | 7540 ± 806 6821 ± 1468 | 7060 ± 817 8537 ± 1304 | 7060 ± 817 8537 ± 1304 |
| SREBP2| 28907 ± 2223       | 30681 ± 864            | 31373 ± 3068 30677 ± 5749 | 29728 ± 3236 30683 ± 5145 | 7060 ± 817 8537 ± 1304 |

Values are given as means ± SEM (standard error of the mean). Significance between the controls and gallstone carriers was analysed with Mann–Whitney U test (nonparametric, two-tailed). P-values <0.05 were considered as statistically significant.

*p = 0.0470 after adjustment (factor 6) *p = 0.282.

NPC1L1 ρ = 0.44, P < 0.0001 and ABCG8/NPC1L1 ρ = 0.12, P = 0.1812.

Furthermore, it was investigated whether gallstone disease is associated with alterations in the major regulatory transcription factors of the sterol transporters as summarized in Table 3. Only for HNF1α an increased transcript expression was observed in overweight gallstone carriers compared to relevant controls (P = 0.0470). None of the other regulatory factors exhibited any significant expression difference between controls and gallstone carriers in general, also not in the different weight groups. Finally, no clear expression correlation of the transcription factors to their respective transporters could be stated (data not shown).

Association of D19H polymorphism with cholelithiasis

Since individuals with the D19H polymorphism (rs11887534, c.52 G > c) in the ABCG8 gene are known to have a higher risk of developing gallstones [29,41], a genotype analysis of this polymorphism was performed in our cohort. The study population was subdivided into weight- and disease-specific subgroups. Genotype frequencies, odds ratios (ORs) and 95% confidence intervals (CI) for each subgroup were calculated to obtain genotype-associated disease risk estimations (Table 4). Moreover, the genotype-associated disease risk was tested by analysing wild type homozygous (GG) individuals compared to the subjects with the heterozygous type (Gc). Confirming prior reports [29,41], D19H was found to be significantly associated with gallstone disease in our total population with OR = 2.9 (P = 0.0020, 95% CI: 1.22–6.89). Notably, overweight simultaneous carriers of gallstones and pD19H displayed a higher OR (OR = 3.2, P = 0.0430, 95% CI: 1.07–9.26) than the respective normal weight group (OR = 1.6, P = 0.6270, 95% CI: 0.30–8.77).

Table 4 The frequency of the polymorphism D19H in the gallstone carriers and controls of the population from Stuttgart

| Group       | Controls (134) | Gallstone carriers (34) | (Gg>gc) |
|-------------|---------------|------------------------|---------|
| Genotype    | G/G | G/c | c/c | G/G | G/c | c/c |
| Total       | 115  | 19  | 0  | 23  | 11  | 0  | 0.022 | 2.9 (CI: 1.216 to 6.889) |
| Normal weight | 66  | 9   | 0  | 9   | 2   | 0  | 0.627 | 1.6 (CI: 0.303 to 8.770) |
| Overweight  | 49   | 10  | 0  | 14  | 9   | 0  | 0.043 | 3.2 (CI: 1.071 to 9.264) |

G = major allele, c = minor allele, OR = odds ratio, CI = confidence interval.

Statistical analysis of genotype frequency differences between gallstone carriers and controls was done using Fisher’s exact test. Odds ratios (ORs) together with a 95% confidence interval (CI) are given as risk measures for the development of gallstones. All statistical tests were two-tailed and a P-value of <0.05 was considered as statistically significant.
gallstone status, cholesterol absorption was consistently lower in carriers of the Gc variant compared with wild type. The most pronounced effect on cholesterol absorption ratio was observed for serum campesterol levels (wild type controls to mutated controls 28%, $P = 0.0347$ and wild type controls to cases with p.D19H 37%, $P = 0.0030$). Regarding the cholesterol synthesis marker lathosterol and serum cholesterol levels, no significant differences were detected between the genotype/phenotype groups (Figure 3C and D).

To study whether this polymorphism affected intestinal transporter expression, the intestinal expression of the $ABCG8$ gene was related to the D19H subgroups. Ileal ABCG8 levels, mRNA as well as protein features, did not differ between controls with and without the SNP, also not in the gallstone group (Figure 4).

**Discussion**

The present study was performed to assess the role of cholesterol metabolism and intestinal transporters as related to the $ABCG8$ 19H risk allele in gallstone disease. Four major observations were made: first, cholesterol absorption was decreased in gallstone carriers but cholesterol synthesis was not significantly different between individuals with gallstones and controls. Second, the ileal expression of the sterol transporters ABGG5, ABCG8 and NPC1L1 as well as of their relevant transcription factors is similar between gallstone carriers and controls. Third, in the cohort of gallstone carriers and controls the D19H polymorphism of the $ABCG8$ gene was associated with a low cholesterol absorption but not with altered de novo synthesis. Fourth, the ileal expression of the $ABCG8$ gene is not influenced by the presence of the mutated allele 19H.

Cholesterol and bile acid homeostasis are clearly altered in gallstone patients compared to a healthy population [3]. Most importantly, body weight influences cholesterol absorption and synthesis [42]. Obesity as well as excessive dietary fat and cholesterol uptake are common characteristics in industrial countries and are tightly related to gallstones [43-46]. Although the combination of multiple risk factors and mechanisms is known to contribute to the hypersaturation with cholesterol, the cause for biliary cholesterol hypersecretion is poorly defined. Cholesterol biosynthesis, biliary secretion, intestinal absorption and fecal loss are the major key steps of cholesterol homeostasis but only absorption and de novo synthesis determine the net body cholesterol supply. Basically, the absorption efficiency of cholesterol in the small intestine is defined by the concurrent influx and efflux of intraluminal cholesterol molecules crossing the apical membrane [47].

Studies in the murine model with deletion of the $ABCG8$ gene observed increased intestinal sterol absorption and reduced hepatic cholesterol secretion [48]. In contrast, overexpression of ABCG5/8 in mice promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol [20]. On the other hand, high cholesterol absorption efficiency and rapid biliary secretion of chylomicron remnant cholesterol enhance cholelithogenesis in gallstone-susceptible mice [49]. Enhanced hepatic expression of ABCG5/8 was already described in Chinese stone-carriers [50] and further studies provide evidence for the functional relevance of hepatic ABCG5/8 expression in relation to the biliary cholesterol secretion [20,51,52].

Measurements of the cholesterol precursor lathosterol allow indirect estimation of de novo cholesterol synthesis and the determination of plant sterols (sitosterol and campesterol) reflects intestinal cholesterol uptake [32,33]. Using this technique our findings are clearly consistent with the observation that cholesterol synthesis is generally higher in overweight persons and the efficiency of cholesterol absorption is reduced [43,46]. Moreover, in the current study a diminished cholesterol absorption ratio...
was noted in gallstone carriers compared to controls. This is in line with previous studies using either the isotope ratio method [3] or also serum surrogate markers [4]. However, there are controversial data regarding cholesterol de novo synthesis. The earlier studies found a decreased cholesterol synthesis in gallstone carriers (with high deoxycholate in bile) [11], whereas Kern found an increased synthesis [3]. In the recent study of Krawczyk reduced intestinal absorption concurred with a (possibly compensatory) enhanced hepatic cholesterol de novo synthesis [4]. However, in the present study the low intestinal cholesterol absorption was not coupled with enhanced hepatic de novo synthesis in gallstone carriers.

Looking for the possible mechanisms determining cholesterol absorption in the gut, the expression of ABCG8, ABCG5 and NPC1L1 as the key intestinal sterol transporters in humans was analysed. Regarding sterol exporter ABCG8 and ABCG5, no significant changes in expression were apparent, also not within the different weight groups. In line with the observation of Masson [53], the levels of
ABCG5 correlated only moderately with those of ABCG8 in our study. Both proteins have different distribution profiles along the intestine and can exhibit variable transporter conformations with each other [54]. Recently, a Chinese study demonstrated an increased intestinal expression of NPC1L1 in gallstone patients as a mechanism for upregulated cholesterol absorption in the small intestine [55]. A decreased hepatic NPC1L1 down-regulation in normal weight female gallstone carriers was already described by Cui [56]. The highest expression levels of the transporter were determined in the jejunum [16] which is not easily accessible.

The polymorphism D19H of sterol exporter ABCG8 was associated with gallstones in various populations and different ethnic groups [29,41,57-61]. In line with prior observations the association with gallstones was confirmed in our population. However, overweight carriers of the ABCG8 19H risk allele displayed a higher OR than normal weight gallstone carriers. Obesity, of course, doubles the gallstone risk and strengthens the metabolic regulatory differences in cholesterol and bile acid homeostasis [3,9,44,46]. In contrast to the study of Srivastava [59], the D19H relative risk was more pronounced in males than in females (Additional file 1: Table S2). This is probably due to a strong effect from the male overweight gallstone group.

Despite these descriptive studies about the relationship of D19H to the abnormalities in the lipid profile or to gallstones [29,41,62,63], there are no direct cell culture studies on the functional influence of the polymorphism on transporter expression or activity so far. Most prior data, however, are compatible with a gain-of-function hypothesis of the 19H allele contributing to the cholesterol supersaturation of bile and the formation of cholesterol gallstones [27,29]. In our study carriers of p.D19H were characterised by significantly reduced intestinal cholesterol absorption irrespective of the presence or absence of gallstones and the polymorphism did not affect intestinal ABCG8 expression. These results are compatible with the findings of Berge [30] in a normal non-gallstone cohort and those of Gylling showing that hypercholesterolemic carriers of the 19H allele exhibited reduced cholesterol absorption as well [31]. Since ABCG5/G8 are sterol exporters, a gain-of-function would lead to diminished absorption with excessive amounts of cholesterol secreted into intestine as well as bile [29,31,41]. It is unclear why in other cohorts [4] there was no association between the 19H risk allele and intestinal cholesterol absorption and also not with gallstones.

**Conclusions**

In summary, both the presence of gallstones and the ABCG8 polymorphism D19H were related to diminished cholesterol absorption but the polymorphism did not affect ileal expression of ABCG8, suggesting a gain-of-function of the mutated transporter. Since cholesterol absorption was also low in gallstone carriers without this polymorphism, this genetic trait does not fully explain this characteristic of gallstone disease.

**Additional file**

Additional file 1: Table S1A. Anthropometric and metabolic characteristics of the Stuttgart study cohort, matched cohort (age, gender and BMI). Table S1B. Detailed comparison of intestinal cholesterol absorption.
absorption surrogate markers according to weight. Table S1C. Anthropometric and metabolic characteristics of the male Stuttgart study cohort. Table S1D. Anthropometric and metabolic characteristics of the female Stuttgart study cohort. Table S2. The frequency of the variant D19H in the gallstone carriers and controls of the population from Stuttgart (with subgroups).

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Conceived and designed the experiments: OR SH. Performed the experiments: AS DR DL OR SS. Contributed reagents/materials/analysis tools: OM. Wrote the paper: OR SH. Supervised the study: SH EFS. All authors read and approved the final manuscript.

Acknowledgements
We are gratefully indebted to Professor Dr. Klaus von Bergmann for valuable initiation of the study measurements of this study. We thank the staff of the gastroenterological department and endoscopy team for recruitment of study participants and collecting tissue biopsies. The authors also thank Dr. Stephan Winter for competent statistical support and Anja Kerkisiek for technical assistance.

Funding
This study was supported by the Robert Bosch Foundation (P4-1/03). The founders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author details
1 Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and Chemistry and Clinical Pharmacology, Laboratory for Special Lipid Diagnostics, University of Bonn, Germany. 2Department of Gastroenterology, Robert Bosch Hospital, 70376 Stuttgart, Germany.

Received: 31 July 2012 Accepted: 12 February 2013
Published: 13 February 2013

References
1. Schafmayer C, Hartleb J, Tepel J, Albers S, Freitag S, Voelzke H, Buch S, Seeger M, Timm B, Kremer B, Foelsch UR, Fändrich F, Krawczyk M, Schreiber S, Hampe J. Predictors of gallstone composition in 1.025 symptomatic gallstones from Northern Germany. BMC Gastroenterol 2006, 6:36.
2. Wang DQ, Carey MC. Complete mapping of crystallization pathways during cholesterol precipitation from model bile: influence of physical-chemical variables of pathophysiological relevance and identification of a stable liquid crystalline state in cold, dilute and hydrophobic bile salt-containing systems. J Lipid Res 1996, 37(3):606–630.
3. Kem F Jr. Effects of dietary cholesterol on cholesterol and bile acid homostasis in patients with cholesterol gallstones. J Clin Invest 1994, 93:1186–1189.
4. Krawczyk M, Lütjohann D, Schien-Sokhan R, Villarroel L, Nervi F, Pimentel F, Lammet F, Miquel F. Phytosterol and cholesterol precursor levels indicate increased cholesterol excretion and biosynthesis in gallstone patients. Hepatology 2012, 55(5):1507–1517. doi: 10.1002/hep.25563.
5. Tufely SD, Dietschy JM. The contribution of newly synthesized cholesterol to biliary cholesterol in the rat. J Biol Chem 1981, 256(7):2438–2446.
6. Scheinber J, Fuchs M, Schiemann M, Tauber G, Hörmann E, Stange EF. Bile acid synthesis from newly synthesized vs. preformed cholesterol precursor pools in the rat. Hepatology 1993, 17(6):1095–1102.
7. Scheinber J, Fuchs M, Hörmann E, Tauber G, Stange EF: Biliary cholesterol secretion and bile acid formation in the hamster: the role of newly synthesized cholesterol. J Lipid Res 1994, 35(4):690–697.
8. Emper K, Lange K, Stange EF, Scheinber J. Newly synthesized cholesterol in human bile and plasma: quantification by mass isotopomer distribution analysis. Am J Physiol 1997, 272(2 Pt 1):G367–G373.
9. Klass DM, Bühmann K, Sauter G, Del Puppo M, Scheinber J, Fuchs M, Stange EF. Biliary lipids, cholesterol and bile synthesis: different adaptive mechanisms to dietary cholesterol in lean and obese subjects. Aliment Pharmacol Ther 2006, 23(7):895–905.
10. Berr F, Pratschke E, Fischer S, Paumgartner G: Disorders of bile acid metabolism in cholesterol gallstone disease. J Clin Invest 1992, 90(3):859–868.
11. Shoda J, He BF, Tanaka N, Matsuzaki Y, Tanimori S, Miyazaki H, Sperovich A. Increase of deoxycholate in super saturated bile of patients with cholesterol gallstone disease and its correlation with de novo syntheses of cholesterol and bile acids in liver, gallbladder epithelial, and small intestinal transit. Hepatology 1995, 21(5):1291–1302.
12. Berghem I, Harisch S, Mueller O, Schimmel S, Fritz P, Stange EF: Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers. J Lipid Res 2006, 47(1):42–50.
13. Renner O, Harisch S, Strohmeyer A, Schimmel S, Stange EF. Reduced ileal expression of OSLalpha OSTbeta in non-obese gallstone disease. J Lipid Res 2008, 49(9):2045–2054.
14. LaMont JT, Carey MC. Cholesterol gallstone formation. 2. Pathobiology and pathomechanics. Prog Liver Dis 1992, 10:165–191.
15. Altmann SW, Davis HR Jr, Zhu LJ, Xao Y, Hoos LM, Teteloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murugolo N, Gratiano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303(5661):1201–1204.
16. Sané AT, Sirett D, Delvin E, Bendayan M, Marcil V, Ménard D, Beaulieu JF, Levy E. Localization and role of NPC1L1 in cholesterol absorption in human intestine. J Lipid Res 2006, 47(10):2112–2120.
17. Davis HR Jr, Zhu LJ, Li Hoos LM, Teteloff G, Maguire M, Liu J, Xao Y, Iyer SP, Lam M-H, Lund EG, Detmers PA, Graziano MP, Altmann SW. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004, 279(32):33586–33592.
18. Duvial C, Touche V, Tailliez A, Frucht JC, Fievet C, Clavey V, Staels B, Lestavel S. Niemann-Pick C1 Like 1 gene expression is down-regulated by FXR activators in the intestine. Biochem Biophys Res Comm 2006, 340(1):1259–1263.
19. Lee MH, Lu K, Hazard S, Yu H, Shulenin S, Hidaka H, Kojima H, Allikmets R, Sakuma N, Pegoraro R, Srivastava AK, Salen G, Dean M, Patel SB: Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 2001, 27(1):79–83.
20. Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC, Hobbs HH: Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest 2002, 110(5):671–680.
21. Kosters A, Fritsjes RJ, Schaap FG, Vink E, Ploos T, Ottenhoff R, Jirsa M, De Cuyper IM, Kuijpers F, Groen AK: Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice. J Hepatol 2003, 38(5):710–716.
22. Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ: Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 2002, 277(21):18793–18800.
23. Pramfalk C, Jiang ZY, Cali Q, Hu H, Zhang SD, Han TQ, Eriksson M, Parini P: HNF1alpha and SREBP2 are important regulators of NPC1L1 in human liver. J Lipid Res 2010, 51(6):1334–1362.
24. van der Veen JN, Kruit JK, Havinga R, Bailer JF, Chimini G, Lestavel S, Staelens S, Baets B, Grooth PH, Groen AK, Kuijpers F: Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J Lipid Res 2005, 46(3):526–534.
25. Wijnaarayage Y, Takada T, Suzuki H: HNF4alpha is a crucial modulator of the cholesterol-dependent regulation of NPC1L1. Pharm Res 2008, 25(5):1134–1141.
26. Wittenburg H, Lyons MA, Paigen B, Carey MC: Mapping cholesterol gallstone susceptibility (Lith) genes in inbred mice. Dig Liver Dis 2003, 35:22–57.
27. Wittenburg H, Lyons MA, Li R, Churchill GA, Carey MC, Paigen B: FXR and ABCG5/ABCG8 as determinants of cholesterol gallstone formation from quantitative trait locus mapping in mice. Gastroenterology 2003, 125(3):868–881.
28. Katsika D, Grijbovski A, Einarsson C, Lammet F, Lichtenstein P, Marschall HU: Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology 2005, 41(2):1138–1143.
29. Buch S, Schaffmayer C, Volzke H, Becker C, Franke A, von Eller-Eberstein H, Kluck C, Bässmann I, Brosch M, Lamert M, Malfijef L, Nef M, Wittig M, Rosskopf D, Timm B, Höll C, Seeger M, Elsharawy A, Lu T, Egberts J, Faendrich F, Foschier UR, Krawczak M, Schreiber S, Nürnberg P, Tepel J, Hampe J. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet 2007, 39(8):995–999.
30. Berge KE, von Bergmann K, Lutjohann D, Guerra R, Grundy SM, Hobbs HH, Cohen JC. Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCGS and ABCGB. J Lipid Res 2002, 43(3):486–494.
31. Gylling H, Hallikainen M, Pihlajamäki J, Agren J, Laakso M, Rajaratnam RA, et al. Effects of dietary vegetable sterol on cholesterol uptake, lymphatic transport, and biliary secretion in Abcg8(−/−) mice. J Lipid Res 2007, 48(4):998–1006.
32. Sudhop T, Lütjohann D, Kodal A, Igel M, Tribe ML, Shah S, Perevozskaya I, et al. Increased gallstone risk in humans linked to reduced expression of ABCG8. J Lipid Res 2009, 50(9):1660–1665.
33. Zamboni M, Mazzali G, Zoico E, Harris TB, Peig ND, et al. Increased expression of LXR alpha, ABCG5, and ABCG8 in mice. Atherosclerosis 2007, 149(1):241–248.
34. Duan LP, Wang HH, Wang DQ. Cholesterol absorption is mainly regulated by the jejunal and ileal ATP-binding cassette sterol efflux transporters Abcg5 and Abcg8 in mice. J Lipid Res 2004, 45(7):1312–13123.
35. Wang HH, Patel SB, Carey MC, Wang DQ. Quantifying aminosalicylic intestinal sterol uptake, lymphatic transport, and biliary secretion in Abcg8(−/−) mice. Hepatology 2007, 45(4):998–1006.
36. Wang DQ, Zeng L, Wang HH. High cholesterol absorption efficiency and rapid biliary secretion of chylomicron remnant cholesterol enhance cholelithogenesis in gallstone-susceptible mice. Biochim Biophys Acta 2005, 1733(1):390–99.
37. Jiang ZY, Parin P, Eggertsen G, Davis MA, Hu H, Suo GJ, Zhang SD, Rudel LL, Han TQ, Einarsson C. Increased expression of LXR alpha, ABCG5, and SR-BI in the liver from nonobese, nonobese Chinese gallstone patients. J Lipid Res 2008, 49(2):464–472.
38. Kamisako T, Ogawa H. Regulation of biliary cholesterol secretion is associated with abcg5 and abcg8 expressions in the rats: effects of diosgenin and ethyl estradiol. Hepatol Res 2003, 26(4):348–352.
39. Wang HH, von Bergmann K, Lutjohann D, Hobbs HH, Cohen JC. Selective sterol accumulation in ABCGS/ABCG8-deficient mice. J Lipid Res 2004, 45(2):301–307.
40. Masson CJ, Plat J, Mensink RP, Niamot A, Kiselevski W, Namitz Z, Füllekrug J, Ehehalt R, Gratz JF, Peters WM. Fatty acid- and cholesterol transporter protein expression along the human intestinal tract. PLoS ONE 2010, 5(4):e10380.
41. Hirata A, Okabe M, Kobayashi A, Ueda K, Matsuo M. Molecular mechanisms of subcellular localization of ABCGS and ABCGB. Biosci Biotechnol Biochem 2009, 73(3):619–626.
42. Jiang ZY, Jiang CY, Wang L, Wang JC, Zhang SD, Einarsson C, Eriksson M, Han TQ, Parin P, Eggertsen G. Increased NPC1L1 and ACAT2 expression in the jejunal mucosa from Chinese gallstone patients. Biochem Biophys Commun 2009, 379(1):49–54.
43. Cui W, Jiang ZY, Cai Q, Zhang Y, Wu WZ, Wang JC, Fei J, Zhang SD, Han TQ. Decreased NPC1L1 expression in the liver from Chinese female gallstone patients. Lipids Health Dis 2010, 9:17.
44. Stenner S, Frikkie-Schmidt R, Nordesgaard BG, Tybjaerg-Hansen A. Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population. Hepatology 2011, 53(2):640–648.
45. Xu HL, Cheng JR, Andreotti G, Gao YT, Rashid A, Wang BS, Shen MC, Chu LW, Yu K, Hsing AW. Cholesterol metabolism gene polymorphisms and the risk of biliary tract cancers and stones: a population-based case–control study in Shanghai, China. Cancer Epidemiol 2011, 35(1):58–62.
46. Srivastava A, Srivastava A, Srivastava K, Koudhuri G, Mittal B. Role of ABCGS D19H (rs11887354) variant in gallstone susceptibility in northern India. J Gastroenterol Hepatol 2010, 25(1):1758–1762.
47. Siddapuram SP, Mahurkar S, Duvvuru NR, Mitnala S, Guduru VR, Rebala P, Mansard M. Hepatic cholesterol transporter ABCGS polymorphisms in gallstone disease in an Indian population. J Gastroenterol Hepatol 2010, 25(6):1093–1098.
48. Kuo KK, Shin SJ, Chen ZC, Yang YH, Yang JF, Hsiao PJ. Significant association of ABCGS 604Q and ABCGS D19H polymorphisms with gallstone disease. Br J Surg 2008, 95(4):1005–1011.
49. Acalovschi M, Ciocan A, Mostean O, Tirziu S, Chiorean E, Keppler H, Schirn-Sohlan R, Lamert M. Are plasma lipid levels related to ABCGS/ABCG8 polymorphisms? A preliminary study in siblings with gallstones. Eur J Intern Med 2006, 17(7):490–494.
50. Chen ZC, Shin SJ, Kuo KK, Lin KD, Yu ML, Hsiao PJ. Significant association of ABCGS D19H gene polymorphism with hypercholesterolemia and insulin resistance. J Hum Genet 2008, 53(5):757–763.